JP2002541849A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002541849A5 JP2002541849A5 JP2000612459A JP2000612459A JP2002541849A5 JP 2002541849 A5 JP2002541849 A5 JP 2002541849A5 JP 2000612459 A JP2000612459 A JP 2000612459A JP 2000612459 A JP2000612459 A JP 2000612459A JP 2002541849 A5 JP2002541849 A5 JP 2002541849A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- amino acid
- vegf variant
- acid substitution
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 27
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 27
- 102220568823 Dual specificity mitogen-activated protein kinase kinase 1_G65V_mutation Human genes 0.000 description 19
- 102200115808 rs10127939 Human genes 0.000 description 19
- 102200006515 rs727503110 Human genes 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 238000000034 method Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 102220366376 c.62A>T Human genes 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102220198097 rs121913236 Human genes 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000004422 Phospholipase C gamma Human genes 0.000 description 1
- 108010056751 Phospholipase C gamma Proteins 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102200006514 rs121913236 Human genes 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12978899P | 1999-04-16 | 1999-04-16 | |
| US60/129,788 | 1999-04-16 | ||
| US18423500P | 2000-02-23 | 2000-02-23 | |
| US60/184,235 | 2000-02-23 | ||
| PCT/US2000/009483 WO2000063380A1 (en) | 1999-04-16 | 2000-04-10 | Vascular endothelial cell growth factor variants and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002541849A JP2002541849A (ja) | 2002-12-10 |
| JP2002541849A5 true JP2002541849A5 (https=) | 2007-06-14 |
Family
ID=26827914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000612459A Pending JP2002541849A (ja) | 1999-04-16 | 2000-04-10 | 血管内皮細胞増殖因子変異体とその用途 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20060063203A1 (https=) |
| EP (2) | EP1655368B1 (https=) |
| JP (1) | JP2002541849A (https=) |
| KR (1) | KR100634926B1 (https=) |
| CN (1) | CN1328376C (https=) |
| AT (2) | ATE329024T1 (https=) |
| AU (1) | AU771042B2 (https=) |
| CA (1) | CA2370246C (https=) |
| DE (2) | DE60041367D1 (https=) |
| ES (2) | ES2265931T3 (https=) |
| HU (1) | HU228898B1 (https=) |
| IL (2) | IL145675A0 (https=) |
| MX (1) | MXPA01010469A (https=) |
| NZ (1) | NZ514488A (https=) |
| WO (1) | WO2000063380A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020473A (en) * | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
| US7078382B1 (en) | 1999-11-02 | 2006-07-18 | Genentech, Inc. | Modulation of eNOS activity and therapeutic uses thereof |
| IL148674A0 (en) * | 1999-11-02 | 2002-09-12 | Genentech Inc | Modulation of enos activity and therapeutic uses thereof |
| US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
| SI1482987T1 (sl) * | 2002-03-01 | 2014-12-31 | Bracco Suisse Sa | Večvalentni konstrukti za terapevtske in diagnostične aplikacije |
| US7211240B2 (en) * | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
| CA2666005C (en) * | 2002-03-01 | 2016-01-19 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| US20050100963A1 (en) | 2002-03-01 | 2005-05-12 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| JP5111729B2 (ja) | 2002-06-05 | 2013-01-09 | ジェネンテック， インコーポレイテッド | 肝成長及び肝保護のための組成物と方法 |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| JP4912144B2 (ja) | 2003-03-12 | 2012-04-11 | ジェネンテック， インコーポレイテッド | 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用 |
| WO2006014678A2 (en) | 2004-07-20 | 2006-02-09 | Genentech, Inc. | Compositions and methods of using angiopoietin-like 4 protein |
| WO2006014729A2 (en) | 2004-07-20 | 2006-02-09 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| CN102614134B (zh) | 2005-03-25 | 2016-09-07 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
| WO2007109183A2 (en) * | 2006-03-20 | 2007-09-27 | Novartis Ag | Mutations and polymorphisms of fms-related tyrosine kinase 1 |
| US7608261B2 (en) | 2006-06-16 | 2009-10-27 | Regeneron Pharmacuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US169292A (en) * | 1875-10-26 | Improvement in butter-packages | ||
| ES2249762T3 (es) * | 1994-03-08 | 2006-04-01 | Human Genome Sciences, Inc. | Factor de crecimiento del endotelio vascular 2. |
| CN1185159A (zh) * | 1995-06-06 | 1998-06-17 | 人体基因组科学有限公司 | 人血管内皮生长因子3 |
| US6020473A (en) * | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
| US6750044B1 (en) * | 1996-10-17 | 2004-06-15 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids |
-
2000
- 2000-04-10 ES ES00921966T patent/ES2265931T3/es not_active Expired - Lifetime
- 2000-04-10 EP EP06000875A patent/EP1655368B1/en not_active Expired - Lifetime
- 2000-04-10 ES ES06000875T patent/ES2320367T3/es not_active Expired - Lifetime
- 2000-04-10 MX MXPA01010469A patent/MXPA01010469A/es active IP Right Grant
- 2000-04-10 JP JP2000612459A patent/JP2002541849A/ja active Pending
- 2000-04-10 EP EP00921966A patent/EP1171594B1/en not_active Expired - Lifetime
- 2000-04-10 KR KR1020017013112A patent/KR100634926B1/ko not_active Expired - Lifetime
- 2000-04-10 CN CNB008081018A patent/CN1328376C/zh not_active Expired - Lifetime
- 2000-04-10 IL IL14567500A patent/IL145675A0/xx unknown
- 2000-04-10 HU HU0200827A patent/HU228898B1/hu unknown
- 2000-04-10 AT AT00921966T patent/ATE329024T1/de active
- 2000-04-10 DE DE60041367T patent/DE60041367D1/de not_active Expired - Lifetime
- 2000-04-10 WO PCT/US2000/009483 patent/WO2000063380A1/en not_active Ceased
- 2000-04-10 AT AT06000875T patent/ATE420177T1/de active
- 2000-04-10 DE DE60028565T patent/DE60028565T2/de not_active Expired - Lifetime
- 2000-04-10 NZ NZ514488A patent/NZ514488A/xx not_active IP Right Cessation
- 2000-04-10 CA CA2370246A patent/CA2370246C/en not_active Expired - Lifetime
- 2000-04-10 AU AU42220/00A patent/AU771042B2/en not_active Expired
-
2001
- 2001-09-25 IL IL145675A patent/IL145675A/en not_active IP Right Cessation
-
2005
- 2005-08-16 US US11/204,554 patent/US20060063203A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002541849A5 (https=) | ||
| Hansson et al. | Regenerating endothelial cells express insulin-like growth factor-I immunoreactivity after arterial injury | |
| Kim et al. | The enhancement of mature vessel formation and cardiac function in infarcted hearts using dual growth factor delivery with self-assembling peptides | |
| ES2327440T3 (es) | Factor recombinante de crecimiento de las celulas endoteliales vasculares-d (vegf-d). | |
| DE60219611T2 (de) | Modifizierte annexin-proteine und verhinderung und behandlung von thrombose | |
| CN105451554B (zh) | 用于治疗血管紧张素相关疾病的方法、化合物和组合物 | |
| AU2019314383B2 (en) | Engineered hemichannels, engineered vesicles, and uses thereof | |
| CN102369026B (zh) | Pcl/pga止血泡沫 | |
| WO2002064157A3 (en) | Localized myocardial injection method for treating ischemic myocardium | |
| DK1266006T3 (da) | Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier | |
| WO2002089856A8 (en) | Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery | |
| JPH03500782A (ja) | 創傷の治癒 | |
| EP2428215A1 (en) | An angiogenesis inducing agent comprising recombinant gelatin | |
| JP2008534594A5 (https=) | ||
| CN115040695B (zh) | 一种基于VE-cad-Fc/N-cad-Fc的融合蛋白活性界面的应用 | |
| CN108753730A (zh) | 一种ntf4基因修饰的脐带间充质干细胞及其构建方法和应用 | |
| HK1048593A1 (zh) | 用於通过体内基因输送治疗心血管疾病的技术和组合物 | |
| WO2003059436A3 (en) | Compositions and methods for promoting myocardial and peripheral angiogenesis | |
| JPH08508511A (ja) | 副行循環の改善への血小板由来成長因子の使用 | |
| NO20060032L (no) | Plasmid som koder for fibroblastvekstfaktor for behandling av hyperkolesterolemi eller diabetesrelaterte angiogeniske defekter | |
| Coronel et al. | Cardiac expression of skeletal muscle sodium channels increases longitudinal conduction velocity in the canine 1-week myocardial infarction | |
| JPH04503960A (ja) | 高発現宿主細胞系からの生物活性血小板由来成長因子の産生 | |
| CN111450119A (zh) | 一种促进器官损伤修复的围产期组织来源的细胞外基质水凝胶制剂 | |
| CN111978405A (zh) | 功能多肽、可特异结合胶原的红细胞载药体系及其应用 | |
| Liu et al. | PRP-loaded pH-responsive hydrogel for the amelioration of ventricular remodeling following myocardial infarction |